PL4129290T3 - Kompozycja farmaceutyczna zawierająca pironarydynę lub jej sól, artemizyninę lub jej pochodną lub kombinację ich obu do zapobiegania lub leczenia choroby układu oddechowego wywołanej przez koronawirusa - Google Patents

Kompozycja farmaceutyczna zawierająca pironarydynę lub jej sól, artemizyninę lub jej pochodną lub kombinację ich obu do zapobiegania lub leczenia choroby układu oddechowego wywołanej przez koronawirusa

Info

Publication number
PL4129290T3
PL4129290T3 PL21775231.0T PL21775231T PL4129290T3 PL 4129290 T3 PL4129290 T3 PL 4129290T3 PL 21775231 T PL21775231 T PL 21775231T PL 4129290 T3 PL4129290 T3 PL 4129290T3
Authority
PL
Poland
Prior art keywords
pyronaridine
artemisinin
coronavirus
derivative
prevention
Prior art date
Application number
PL21775231.0T
Other languages
English (en)
Inventor
Jei Man Ryu
Chung Ju
Hyun Kyu Chung
Geum Sil CHO
Original Assignee
Shin Poong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Poong Pharmaceutical Co., Ltd. filed Critical Shin Poong Pharmaceutical Co., Ltd.
Publication of PL4129290T3 publication Critical patent/PL4129290T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21775231.0T 2020-03-26 2021-03-25 Kompozycja farmaceutyczna zawierająca pironarydynę lub jej sól, artemizyninę lub jej pochodną lub kombinację ich obu do zapobiegania lub leczenia choroby układu oddechowego wywołanej przez koronawirusa PL4129290T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200037135 2020-03-26
PCT/KR2021/003742 WO2021194290A1 (ko) 2020-03-26 2021-03-25 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물

Publications (1)

Publication Number Publication Date
PL4129290T3 true PL4129290T3 (pl) 2025-10-13

Family

ID=77892085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21775231.0T PL4129290T3 (pl) 2020-03-26 2021-03-25 Kompozycja farmaceutyczna zawierająca pironarydynę lub jej sól, artemizyninę lub jej pochodną lub kombinację ich obu do zapobiegania lub leczenia choroby układu oddechowego wywołanej przez koronawirusa

Country Status (18)

Country Link
US (1) US12485116B2 (pl)
EP (1) EP4129290B1 (pl)
JP (1) JP7894319B2 (pl)
KR (2) KR102828536B1 (pl)
CN (1) CN115666572B (pl)
BR (1) BR112022019198A2 (pl)
CL (1) CL2022002588A1 (pl)
CO (1) CO2022014992A2 (pl)
CR (1) CR20220508A (pl)
EC (1) ECSP22081150A (pl)
ES (1) ES3040436T3 (pl)
IL (1) IL296721A (pl)
MX (1) MX2022011885A (pl)
PE (1) PE20230041A1 (pl)
PH (1) PH12022552516A1 (pl)
PL (1) PL4129290T3 (pl)
UA (1) UA130231C2 (pl)
WO (1) WO2021194290A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111803491A (zh) * 2020-07-24 2020-10-23 中国人民解放军军事科学院军事医学研究院 青蒿素类化合物在治疗冠状病毒感染方面的应用
WO2022076565A1 (en) * 2020-10-07 2022-04-14 Sorrento Therapeutics, Inc. Salicylanilide analogs for use in the treatment of coronavirus
US20250177419A1 (en) * 2022-03-08 2025-06-05 Webiotree Co., Ltd Pharmaceutical composition comprising niclosamide or pharmaceutically acceptable salt thereof and preparation method therefor
WO2025153638A1 (en) * 2024-01-19 2025-07-24 Pamoja Therapeutics Bv Highly concentrated liquid aqueous pyronaridine formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
ES2353384T3 (es) * 2003-02-12 2011-03-01 Georgetown University Uso de artemisinina para tratar tumores inducidos por virus oncogénicos y para tratar infecciones víricas.
US20110206636A1 (en) * 2003-09-16 2011-08-25 Kemin Foods, LLC Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
KR100623322B1 (ko) * 2004-11-02 2006-09-19 신풍제약주식회사 경구투여용 항말라리아 배합 제제 및 그의 제조방법
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
CN101857613B (zh) * 2010-06-03 2012-04-18 中国科学院新疆理化技术研究所 一枝蒿酮酸糖酯类衍生物及其制备方法和用途
CN101898966B (zh) * 2010-07-15 2013-04-17 中国科学院新疆理化技术研究所 含哌嗪环的一枝蒿酮酸酯类衍生物及其制备方法
JP5750274B2 (ja) * 2011-02-15 2015-07-15 株式会社ブリヂストン ゴムクローラ
US9675582B2 (en) * 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US20140011829A1 (en) * 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease
CN105168500B (zh) * 2015-09-11 2018-08-17 青岛大学附属医院 一种用于治疗小儿口腔溃疡的药物组合物及其制备方法
US11696914B1 (en) * 2019-11-06 2023-07-11 Collaborations Pharmaceuticals, Inc. Use of pyronaridine, tilorone, and quinacrine against Marburg virus and other virus infections
CN115968285A (zh) * 2020-03-18 2023-04-14 Gmp生物技术有限公司 TGF-β抑制、用于其的药剂及组合物

Also Published As

Publication number Publication date
AU2021244009A1 (en) 2022-10-27
EP4129290A1 (en) 2023-02-08
ES3040436T3 (en) 2025-10-30
US20230132036A1 (en) 2023-04-27
CL2022002588A1 (es) 2023-05-26
JP2023519277A (ja) 2023-05-10
CO2022014992A2 (es) 2022-11-29
CN115666572A (zh) 2023-01-31
KR102910416B1 (ko) 2026-01-14
IL296721A (en) 2022-11-01
BR112022019198A2 (pt) 2022-11-16
CN115666572B (zh) 2025-03-28
MX2022011885A (es) 2022-10-21
CR20220508A (es) 2023-04-25
EP4129290B1 (en) 2025-07-09
UA130231C2 (uk) 2025-12-24
EP4129290C0 (en) 2025-07-09
PH12022552516A1 (en) 2022-11-07
US12485116B2 (en) 2025-12-02
WO2021194290A1 (ko) 2021-09-30
KR20240108337A (ko) 2024-07-09
CA3172672A1 (en) 2021-09-30
KR102828536B1 (ko) 2025-07-02
JP7894319B2 (ja) 2026-07-23
KR20210120891A (ko) 2021-10-07
EP4129290A4 (en) 2023-08-30
ECSP22081150A (es) 2023-02-28
PE20230041A1 (es) 2023-01-10

Similar Documents

Publication Publication Date Title
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
NO20074620L (no) Spiroheterocykliske forbindelser og deres anvendelse som medikamenter
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2007015863A (es) Inhibidores de esfingosina cinasa.
EA200702200A1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
UY28692A1 (es) Nuevos derivados de quinolina
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
BRPI1007737A2 (pt) "composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
BRPI1007092B8 (pt) Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX382765B (es) Tratamiento para la colangitis biliar primaria.
EP4129290C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING PYRONARYIDINE OR A SALT THEREOF, ARTEMISININ OR A DERIVATIVE THEREOF OR A COMBINATION OF THE TWO FOR PREVENTING OR TREATING A RESPIRATORY DISEASE CAUSED BY A CORONAVIRUS
MX2014002465A (es) Composiciones acuosas que comprenden arbekacina.
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
GEP20115222B (en) New pharmaceutical compounds
WO2007104933A8 (en) Chemical compounds
BR112013012665A2 (pt) composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica